IL1B and hypertensive disorder: Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provided the opportunity to test whether IL-1β inhibition would reduce BP, prevent incident HTN, and modify the relationships between HTN and cardiovascular events.